GleamWall
中文EN

PMVP PMV Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1699382 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-7.0%
TTM EPS YoY1.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-99.4%
ROA-72.2%
ROIC (approx.)-100.2%
Asset turnover—

Leverage & solvency

Liabilities / assets48.7%
Debt / equity0.00x
Current ratio9.81x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-15.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$69.88M$58.53M
SG&A expense$16.33M$26.92M
Operating income-$86.21M-$85.45M
Pretax income-$79.91M-$74.81M
Income tax-$2.17M-$16.10M
Net income-$77.74M-$58.71M
EBITDA-$86.07M-$84.30M
EPS (basic)-1.48-1.14
EPS (diluted)-1.48-1.14
Weighted avg. shares (diluted)52.54M51.58M
Banking
Net interest income$6.34M$10.65M
Balance sheet
Cash & equivalents$37.98M$40.88M
Short-term investments$74.96M$128.58M
Current assets$115.23M$175.66M
PP&E, net$237,000$409,000
Total assets$116.56M$191.29M
Current liabilities$11.41M$14.37M
Total liabilities$11.85M$15.21M
Shareholders' equity$104.71M$176.08M
Shares outstanding53.33M51.94M
Cash flow statement
Operating cash flow-$73.58M-$51.28M
Capital expenditure$29,000$655,000
Free cash flow-$73.61M-$51.94M
Investing cash flow$70.17M$53.35M
Financing cash flow$505,000$313,000
Depreciation & amortization$133,000$1.14M
Stock-based compensation$5.92M$8.87M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.